Abbott Laboratories: Dividend Hike and Acquisition Speculation Drive Investor Focus
Published on 12/18/2025 at 07:51 | Redaktion boerse-global.de
Abbott Laboratories has announced an increase to its shareholder payout while simultaneously revealing mixed institutional trading activity. These developments coincide with market rumors regarding a potential acquisition, creating a multifaceted narrative for investors to consider.
The company’s third-quarter results met key expectations. Adjusted earnings per share came in at $1.30, aligning with consensus estimates. Revenue reached $11.37 billion, marking a solid 6.9% year-over-year increase, though it slightly missed projections of $11.40 billion. Management provided a narrowed and confirmed outlook for 2025, forecasting adjusted EPS in the range of $5.12 to $5.18. They anticipate organic sales growth, excluding COVID-19 test-related revenue, to be between 7.5% and 8.0%. Challenges persist in the diagnostics segment, pressured by declining demand for COVID tests Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
